TEST BANK FOR PHARMACOTHERAPEUTICS FOR ADVANCED
PRACTICE 5TH EDITION BY ARCANGELO, PETERSON, WILBUR &
KANG 0VER 250 QUESTIONS AND CORRECT ANSWERS
Core Principles and Pharmacokinetics
1. Question: Which regulatory body or entity determines the specific prescriptive authority for a nurse
practitioner within a given U.S. state? Answer: The State Board of Nursing for each individual state.
2. Question: Define pharmacodynamics in the context of advanced drug therapy. Answer: The study of
the biochemical and physiological effects of drugs on the body and their mechanisms of action.
3. Question: What term describes the fraction of an administered dose of unchanged drug that reaches
the systemic circulation? Answer: Bioavailability.
4. Question: Which phase of drug metabolism primarily involves oxidation, reduction, or hydrolysis
reactions via the cytochrome P450 enzyme system? Answer: Phase I metabolism.
5. Question: What is the primary clinical consequence of enzyme induction by a concurrently
administered medication? Answer: Decreased plasma concentrations and reduced therapeutic
efficacy of the affected substrate drug.
6. Question: Which pharmacokinetic process is most directly affected by severe renal impairment
measured via creatinine clearance? Answer: Drug elimination and excretion.
7. Question: What pharmacokinetic barrier protects the central nervous system by restricting the
passage of polar and high-molecular-weight substances? Answer: The blood-brain barrier.
8. Question: What is the primary goal of establishing a steady-state drug concentration? Answer: To
maintain a constant therapeutic drug level within the therapeutic window where rate of drug
administration equals rate of elimination.
Prescribing Across the Lifespan and Special Populations
9. Question: Why is total body water percentage significantly higher in neonates compared to adults
when calculating hydrophilic drug dosages? Answer: Neonates have a higher extracellular fluid
volume, which increases the volume of distribution for water-soluble medications.
10. Question: Which physiological change in older adults most significantly impacts the clearance of
renally excreted medications? Answer: Decreased glomerular filtration rate (GFR).
11. Question: What screening tool is widely utilized in clinical practice to identify potentially
inappropriate medications in older adults? Answer: The Beers Criteria.
12. Question: During pregnancy, which physiological adaptation increases the hepatic metabolism and
renal elimination of many drugs? Answer: Increased renal blood flow and enhanced glomerular
filtration rate.
,13. Question: Why are tetracyclines strictly contraindicated during the second and third trimesters of
pregnancy and in young children? Answer: They bind to calcium, causing permanent tooth
discoloration, enamel hypoplasia, and inhibition of bone growth.
14. Question: What clinical risk is associated with administering sulfonamides near term to a pregnant
woman? Answer: Kernicterus in the newborn due to the displacement of bilirubin from plasma
proteins.
15. Question: Which pharmacokinetic parameter is altered in pediatric patients due to lower plasma
protein concentrations (such as albumin)? Answer: Increased free (unbound) fraction of highly
protein-bound drugs, enhancing pharmacological and toxic effects.
16. Question: What is the primary pharmacotherapeutic concern when prescribing lipid-soluble
medications to breastfeeding women? Answer: Lipid-soluble drugs easily cross into breast milk and
can be ingested by the nursing infant.
17. Question: Which age group experiences rapid maturation of hepatic enzyme systems, often
requiring higher weight-based drug doses for certain medications compared to neonates? Answer:
Infants and toddlers (pediatric population past the neonatal period).
18. Question: What specialized term describes the study of how genetic variations influence individual
responses to drug therapy? Answer: Pharmacogenomics.
Pain Management and Substance Use Disorders
19. Question: What is the primary mechanism of action of full opioid receptor agonists such as
morphine? Answer: Binding to and activating mu-opioid receptors in the central nervous system to
inhibit ascending pain pathways.
20. Question: Which medication is a potent synthetic opioid antagonist used to rapidly reverse acute
opioid overdose? Answer: Naloxone.
21. Question: What unique pharmacological property does buprenorphine possess that makes it
effective in treating opioid use disorder (OUD)? Answer: It acts as a partial mu-opioid agonist with a
high receptor affinity, ceiling effect for respiratory depression, and strong antagonist properties at
higher doses.
22. Question: Which co-analgesic class is first-line for treating neuropathic pain conditions such as
diabetic peripheral neuropathy or post-herpetic neuralgia? Answer: Alpha-2-delta ligands
(gabapentinoids, such as gabapentin and pregabalin).
23. Question: What serious adverse effect must clinicians monitor for when combining opioids with
central nervous system depressants like benzodiazepines? Answer: Profound respiratory depression
and fatal sedation.
24. Question: Which neurotransmitters are primarily modulated by cannabis and its constituent
phytocannabinoids interacting with human CB1 and CB2 receptors? Answer: Endocannabinoids
(anandamide and 2-arachidonoylglycerol), influencing GABAergic and glutamatergic
transmission.
, 25. Question: What is the mechanism of action of nonsteroidal anti-inflammatory drugs (NSAIDs)?
Answer: Inhibition of cyclooxygenase (COX-1 and COX-2) enzymes, thereby blocking the
synthesis of pro-inflammatory prostaglandins.
26. Question: Which gastrointestinal protective agent is frequently co-prescribed with chronic NSAID
therapy to prevent peptic ulcer disease? Answer: Proton pump inhibitors (PPIs) such as misoprostol
or omeprazole.
27. Question: What critical laboratory parameters must be monitored periodically in patients receiving
long-term NSAID therapy? Answer: Serum creatinine, blood urea nitrogen (BUN), complete blood
count (for occult bleeding), and liver function tests.
28. Question: Define physical dependence in the context of opioid therapy. Answer: A physiological
adaptation characterized by the emergence of a withdrawal syndrome upon abrupt cessation or
rapid dose reduction of a substance.
Cardiovascular Disorders
29. Question: What is the primary mechanism of action of thiazide diuretics (e.g., hydrochlorothiazide)
in hypertension? Answer: Inhibition of sodium and chloride reabsorption in the distal convoluted
tubule, leading to initial diuresis and sustained vasodilation.
30. Question: Which class of antihypertensive medications is contraindicated in patients with bilateral
renal artery stenosis? Answer: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin
receptor blockers (ARBs).
31. Question: What troublesome adverse effect commonly prompts patients to discontinue ACE
inhibitor therapy? Answer: Persistent dry, hacking cough caused by the accumulation of
bradykinin.
32. Question: How do beta-blockers reduce myocardial oxygen demand in chronic stable angina?
Answer: By decreasing heart rate, myocardial contractility, and systemic blood pressure.
33. Question: Which lipid-lowering drug class works by inhibiting 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase? Answer: Statins (e.g., atorvastatin, rosuvastatin).
34. Question: What severe and potentially fatal muscle toxicity must clinicians monitor for in patients
taking statins, especially when combined with CYP3A4 inhibitors? Answer: Rhabdomyolysis.
35. Question: What is the mechanism of action of cardiac glycosides like digoxin? Answer: Inhibition
of the Na+/K+-ATPase membrane pump, leading to increased intracellular calcium and positive
inotropic effects.
36. Question: Which electrolyte abnormality significantly increases the risk of digoxin toxicity?
Answer: Hypokalemia.
37. Question: What class of antiarrhythmic medications works primarily by blocking cardiac sodium
channels? Answer: Class I antiarrhythmics.
38. Question: Which oral anticoagulant is a direct thrombin inhibitor? Answer: Dabigatran.
PRACTICE 5TH EDITION BY ARCANGELO, PETERSON, WILBUR &
KANG 0VER 250 QUESTIONS AND CORRECT ANSWERS
Core Principles and Pharmacokinetics
1. Question: Which regulatory body or entity determines the specific prescriptive authority for a nurse
practitioner within a given U.S. state? Answer: The State Board of Nursing for each individual state.
2. Question: Define pharmacodynamics in the context of advanced drug therapy. Answer: The study of
the biochemical and physiological effects of drugs on the body and their mechanisms of action.
3. Question: What term describes the fraction of an administered dose of unchanged drug that reaches
the systemic circulation? Answer: Bioavailability.
4. Question: Which phase of drug metabolism primarily involves oxidation, reduction, or hydrolysis
reactions via the cytochrome P450 enzyme system? Answer: Phase I metabolism.
5. Question: What is the primary clinical consequence of enzyme induction by a concurrently
administered medication? Answer: Decreased plasma concentrations and reduced therapeutic
efficacy of the affected substrate drug.
6. Question: Which pharmacokinetic process is most directly affected by severe renal impairment
measured via creatinine clearance? Answer: Drug elimination and excretion.
7. Question: What pharmacokinetic barrier protects the central nervous system by restricting the
passage of polar and high-molecular-weight substances? Answer: The blood-brain barrier.
8. Question: What is the primary goal of establishing a steady-state drug concentration? Answer: To
maintain a constant therapeutic drug level within the therapeutic window where rate of drug
administration equals rate of elimination.
Prescribing Across the Lifespan and Special Populations
9. Question: Why is total body water percentage significantly higher in neonates compared to adults
when calculating hydrophilic drug dosages? Answer: Neonates have a higher extracellular fluid
volume, which increases the volume of distribution for water-soluble medications.
10. Question: Which physiological change in older adults most significantly impacts the clearance of
renally excreted medications? Answer: Decreased glomerular filtration rate (GFR).
11. Question: What screening tool is widely utilized in clinical practice to identify potentially
inappropriate medications in older adults? Answer: The Beers Criteria.
12. Question: During pregnancy, which physiological adaptation increases the hepatic metabolism and
renal elimination of many drugs? Answer: Increased renal blood flow and enhanced glomerular
filtration rate.
,13. Question: Why are tetracyclines strictly contraindicated during the second and third trimesters of
pregnancy and in young children? Answer: They bind to calcium, causing permanent tooth
discoloration, enamel hypoplasia, and inhibition of bone growth.
14. Question: What clinical risk is associated with administering sulfonamides near term to a pregnant
woman? Answer: Kernicterus in the newborn due to the displacement of bilirubin from plasma
proteins.
15. Question: Which pharmacokinetic parameter is altered in pediatric patients due to lower plasma
protein concentrations (such as albumin)? Answer: Increased free (unbound) fraction of highly
protein-bound drugs, enhancing pharmacological and toxic effects.
16. Question: What is the primary pharmacotherapeutic concern when prescribing lipid-soluble
medications to breastfeeding women? Answer: Lipid-soluble drugs easily cross into breast milk and
can be ingested by the nursing infant.
17. Question: Which age group experiences rapid maturation of hepatic enzyme systems, often
requiring higher weight-based drug doses for certain medications compared to neonates? Answer:
Infants and toddlers (pediatric population past the neonatal period).
18. Question: What specialized term describes the study of how genetic variations influence individual
responses to drug therapy? Answer: Pharmacogenomics.
Pain Management and Substance Use Disorders
19. Question: What is the primary mechanism of action of full opioid receptor agonists such as
morphine? Answer: Binding to and activating mu-opioid receptors in the central nervous system to
inhibit ascending pain pathways.
20. Question: Which medication is a potent synthetic opioid antagonist used to rapidly reverse acute
opioid overdose? Answer: Naloxone.
21. Question: What unique pharmacological property does buprenorphine possess that makes it
effective in treating opioid use disorder (OUD)? Answer: It acts as a partial mu-opioid agonist with a
high receptor affinity, ceiling effect for respiratory depression, and strong antagonist properties at
higher doses.
22. Question: Which co-analgesic class is first-line for treating neuropathic pain conditions such as
diabetic peripheral neuropathy or post-herpetic neuralgia? Answer: Alpha-2-delta ligands
(gabapentinoids, such as gabapentin and pregabalin).
23. Question: What serious adverse effect must clinicians monitor for when combining opioids with
central nervous system depressants like benzodiazepines? Answer: Profound respiratory depression
and fatal sedation.
24. Question: Which neurotransmitters are primarily modulated by cannabis and its constituent
phytocannabinoids interacting with human CB1 and CB2 receptors? Answer: Endocannabinoids
(anandamide and 2-arachidonoylglycerol), influencing GABAergic and glutamatergic
transmission.
, 25. Question: What is the mechanism of action of nonsteroidal anti-inflammatory drugs (NSAIDs)?
Answer: Inhibition of cyclooxygenase (COX-1 and COX-2) enzymes, thereby blocking the
synthesis of pro-inflammatory prostaglandins.
26. Question: Which gastrointestinal protective agent is frequently co-prescribed with chronic NSAID
therapy to prevent peptic ulcer disease? Answer: Proton pump inhibitors (PPIs) such as misoprostol
or omeprazole.
27. Question: What critical laboratory parameters must be monitored periodically in patients receiving
long-term NSAID therapy? Answer: Serum creatinine, blood urea nitrogen (BUN), complete blood
count (for occult bleeding), and liver function tests.
28. Question: Define physical dependence in the context of opioid therapy. Answer: A physiological
adaptation characterized by the emergence of a withdrawal syndrome upon abrupt cessation or
rapid dose reduction of a substance.
Cardiovascular Disorders
29. Question: What is the primary mechanism of action of thiazide diuretics (e.g., hydrochlorothiazide)
in hypertension? Answer: Inhibition of sodium and chloride reabsorption in the distal convoluted
tubule, leading to initial diuresis and sustained vasodilation.
30. Question: Which class of antihypertensive medications is contraindicated in patients with bilateral
renal artery stenosis? Answer: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin
receptor blockers (ARBs).
31. Question: What troublesome adverse effect commonly prompts patients to discontinue ACE
inhibitor therapy? Answer: Persistent dry, hacking cough caused by the accumulation of
bradykinin.
32. Question: How do beta-blockers reduce myocardial oxygen demand in chronic stable angina?
Answer: By decreasing heart rate, myocardial contractility, and systemic blood pressure.
33. Question: Which lipid-lowering drug class works by inhibiting 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase? Answer: Statins (e.g., atorvastatin, rosuvastatin).
34. Question: What severe and potentially fatal muscle toxicity must clinicians monitor for in patients
taking statins, especially when combined with CYP3A4 inhibitors? Answer: Rhabdomyolysis.
35. Question: What is the mechanism of action of cardiac glycosides like digoxin? Answer: Inhibition
of the Na+/K+-ATPase membrane pump, leading to increased intracellular calcium and positive
inotropic effects.
36. Question: Which electrolyte abnormality significantly increases the risk of digoxin toxicity?
Answer: Hypokalemia.
37. Question: What class of antiarrhythmic medications works primarily by blocking cardiac sodium
channels? Answer: Class I antiarrhythmics.
38. Question: Which oral anticoagulant is a direct thrombin inhibitor? Answer: Dabigatran.
